Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
University of Alabama at Birmingham
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06320951CT.gov VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vericiguat (this asset) | University of Alabama at Birmingham | P2 | CCC · 53 |
| Liraglutide | Anders Fink-Jensen, MD, DMSci | P4 | A |
| Semaglutide | Nordsjaellands Hospital | P4 | A |
| Metformin | Jinnah Sindh Medical University | P4 | BBB |
| Tirzepatide | Washington University School of Medicine | P4 | BBB |
| Pravastatin | National Human Genome Research Institute (NHGRI) | P4 | BBB |
| Midazolam | Baskent University | P4 | BB |
| Retrovir | Kirby Institute | P4 | BB |
| Hydrochlorothiazide | Vanderbilt University Medical Center | P3 | BB |
+42 more in the Metabolic Disease cohort
Other indications for Vericiguat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Coronary Microvascular Disorder | — | P2 | B · 57 |
| Abdominal Obesity-Metabolic Syndrome | — | P2 | CCC · 54 |
| Heart Failure | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vericiguat in Metabolic Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vericiguat-metabolic-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →